Resilience Stock

resilience.comHealthcare / BioTech & PharmaFounded: 2020Funding to Date: $2.03B

Resilience is a biomanufacturing business focusing on pharmaceuticals. Their team is focused on producing complex solutions such as gene therapies, vaccines, and cell therapies. Resilience was founded in 2020 by Drew Oetting, Patrick Yang Ph.D, Sandesh Mahatme, and Rahul Singhvi Ph.D and is headquartered in La Jolla, CA.

Register To Buy and Sell Shares

For more details on private stock price information, financing and valuation for Resilience, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Resilience’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Resilience.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Resilience investors also invested in these private companies

Dragoeer Investment Group
Mubadala Investment Company
Global Health Investment Fund


Management Team

Syed Husain
Chief Commercial Officer
Elliot Menschik Ph.D
Chief Digital Officer
Spencer Fisk
Chief Technology Officer
Ori Solomon JD
Chief Legal Officer, General Counsel
Duane Avant
Chief Quality Officer
Viet Nguyen
Chief Manufacturing Officer
Rahul Singhvi Ph.D
Co-Founder, Chief Executive Officer & Board Member
Sandesh Mahatme
Co-Founder, President, Chief Financial Officer & Chief Operating Officer
Drew Oetting
Co-Founder & Board Member
Patrick Yang

Board Members

Scott Gottlieb MD
New Enterprise Associates
Susan Desmond-Hellmann MD

Resilience’s stock FAQs


Can you buy Resilience’s stock?

As Resilience is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like Resilience, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge's Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.

How to buy Resilience’s stock?

To invest in a private company like Resilience’s through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)
  1. Create a free account to access Forge's marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Resilience’s stock?

Yes, you may be able to sell your Resilience’s stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Resilience’s stock?

If you hold private company shares of Resilience’s - whether as an employee or an early investor - Forge can help you sell them.
  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Resilience’s on our platform.
  3. Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.

Is Resilience’s a public company?

No, Resilience’s is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Resilience’s stock price?

Resilience is a privately held company and therefore does not have a public stock price. However, you may access Resilience’s private market stock price with Forge Data.

What is Resilience’s stock ticker symbol?

Resilience does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

On the defense: Resilience bags $410m US Gov contract

The $410 million long-term funding agreement with the US Department of Defense (DoD), in collaboration with the US International Development Finance Corporation (DFC), aims to support Resilience’s capabilities and strengthen domestic bioproduction.

As US plots biomanufacturing boost, National Resilience nets $410M loan from Defense Department

Amid a spate of drug production pledges from the White House, U.S.-based manufacturer National Resilience has scored new government financing to keep its mission running for the long haul.

AstraZeneca to sell Ohio site to biotech firm Resilience

AstraZeneca is selling its West Chester manufacturing site in Ohio in the United States to biomanufacturing company National Resilience Inc, the company said on Tuesday.
Updated on: Jul 24, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.